Exosomes Scientific Signature Series

Special Add-on Pricing with ISCT 2026

The Exosomes Scientific Signature Series brings together global experts to examine the evolving science, translation, and clinical application of extracellular vesicles (EVs) and the broader secretome. The program focuses on defining and measuring active components, understanding analytical and manufacturing limitations, and interpreting early clinical experience, while addressing key challenges such as standardization, reproducibility, scalability, and regulatory expectations to support safe and consistent clinical translation.

CAR-T Scientific Signature Series

Special Add-on Pricing with ISCT 2026

The CAR-T Scientific Signature Series explores the expansion of CAR-T cell therapies beyond hematologic malignancies into new disease areas, including autoimmune, fibrotic, cardiovascular, and neurological conditions. Through expert-led discussions, the program examines emerging clinical applications, in vivo CAR-T development, trial design for novel indications, regional regulatory expectations, and reimbursement considerations shaping broader clinical adoption.

ISCT Global Regulators Summit

From Reliance to Resilience: Advancing Collaboration in CGT to Support Global Regulatory Development
Tuesday, May 5, 2026 • Closed, Invitation-Only Event

The 4th ISCT Annual Global Regulators Summit will bring together representatives from international regulatory agencies to collaboratively examine the current landscape of regulatory work-sharing initiatives and models for cell and gene therapy products. The dialogue will center on fostering global regulatory alignment and consensus, while also advancing inclusive collaboration strategies that empower low- and middle-income countries (LMICs) in the development and oversight of cell and gene therapy products.

 The summit will address:

1. Assess Current Work-Sharing and Collaboration Models: conduct a thorough review of existing work-sharing initiatives and regulatory collaboration frameworks, evaluating their effectiveness, efficiency, and relevance to the Cell and Gene Therapy (CGT) field.
2. Explore Implementation Challenges: facilitate stakeholder engagement to identify key challenges and barriers to implementing current collaborative approaches in CGT, particularly within low and middle-income countries (LMICs), where regulatory gaps and resource constraints may limit patient access to CGT products.
3. Identify Opportunities for Enhanced Collaboration: pinpoint specific areas for strengthening regulatory collaboration and work-sharing among agencies, with a focus on post-marketing evidence generation, integration of real-world data into regulatory decision-making, and capacity-building efforts to support regulatory development in LMICs.

The unprecedented event in 2025 brought together key regulatory leaders and experts from 13 global regulatory agencies and government organizations to address and enhance understanding of the global regulatory landscape for gaining and maintaining accelerated approval for cell and gene therapy products. Agencies and organizations included ANVISA (Brazil), CAT-EMA (European Union), HSA (Singapore), ICMR (India), ISPCH (Chile), MHLW (Japan), NDA (Uganda), NPRA (Malaysia), PMDA (Japan), SFDA (Saudi Arabia), Swissmedic (Switzerland),  TFDA (Taiwan), and TGA (Australia).

ISCT Commercialization Signature Series

Manufacturing for Adoption: Bridging Process Innovation and Clinical Reality
Tuesday, May 5, 2026 • Closed, Industry Patron Member Exclusive Event 

The ISCT Commercialization Signature Series (CSS) is an exclusive, industry-driven event that convenes leading experts across the cell and gene therapy (CGT) commercialization pipeline to address critical barriers hindering sector progress . The 2026 CSS will focus on how commercial success in CGT depends on scalable, digitized manufacturing that has been designed with clinical integration in mind.

The session will examine the most pressing infrastructure, technological, and liability challenges facing the field, with the aim of identifying where the industry can collectively align to accelerate adoption. Industry leaders, regulatory authorities, and CGT pioneers will each be in attendance, collaborating to develop actionable solutions to drive enhanced adoption. 

Key outcomes from the session will be captured in a consensus position paper for submission to Cytotherapy, the ISCT Scientific Journal.

Interested in joining ISCT as a Patron Member? Find out more.